GOLD COPD Exacerbation History Categories and Disease Outcomes

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2024 Dec 18

PMID 39693071

Authors

Kiki Waeijen-Smit

Daphne E M Peerlings

Rudolf A Jorres

Henrik Watz

Robert Bals

Klaus F Rabe

Claus F Vogelmeier

Tim Speicher

Martijn A Spruit

Sami O Simons

Sarah Houben-Wilke

Frits M E Franssen

Peter Alter

Affiliations

Soon will be listed here.

Abstract

Importance: Previous exacerbations of chronic obstructive pulmonary disease (ECOPD) are associated with future events. For more than a decade, patients at high risk have been defined as individuals with a history of 2 or more moderate ECOPD, 1 or more severe ECOPD, or both within 12 months, and treatments have been allocated accordingly, but these cutoffs lack validation.

Objectives: To validate ECOPD history categories by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and explore alternative cutoffs to estimate moderate and severe ECOPD and all-cause mortality in COPD.

Design, Setting, And Participants: This cohort study analyzed data from patients with COPD in the German COPD and Systemic Consequences-Comorbidities Network (COSYCONET) study. Patients were recruited from September 2010 to December 2013. Analyses were conducted in September 2023 to August 2024.

Main Outcomes And Measures: Risk of moderate and severe (ie, with hospitalization) ECOPD and all-cause mortality over a 4.5-year follow-up period were assessed using binomial logistic regressions and area under the receiver operating characteristic curves (AUROCs) with 95% CIs.

Results: Among 2291 patients with COPD GOLD categories 1 to 4 (mean [SD] age, 65 [8] years; 1396 male [60.9%]), the mean (SD) estimated forced expiratory volume in the first second of expiration was 52.5% (18.6%). ECOPD history categories by GOLD had an AUROC of 0.63 (95% CI, 0.60-0.65) and 0.62 (95% CI, 0.58-0.66) to estimate moderate and severe ECOPD, respectively. A single previous moderate ECOPD within 12 months more accurately estimated future moderate and severe ECOPD (AUROC, 0.66; 95% CI, 0.64-0.69), and in line with GOLD, 1 previous severe ECOPD within 12 months estimated moderate and severe ECOPD (AUROC, 0.63; 95% CI, 0.60-0.67). The 4-year mortality rate was 219 patients (9.6%). Patients with 3 or more previous moderate ECOPD (odds ratio, 2.18; 95% CI, 1.27-3.72) or 1 or more previous severe ECOPD (odds ratio, 1.57; 95% CI, 1.29-1.91) within 12 months were more likely to die compared with patients without prior ECOPD.

Conclusions And Relevance: This study's findings suggest a limited estimative performance of ECOPD history categories by GOLD. Novel cutoffs were suggested, categorizing patients as without exacerbations or with high-risk exacerbations based on a history of 1 or more moderate ECOPD, 1 or more severe ECOPD, or both within 12 months.

References

Karch A, Vogelmeier C, Welte T, Bals R, Kauczor H, Biederer J . The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016; 114:27-37. DOI: 10.1016/j.rmed.2016.03.008. View

Lipson D, Barnhart F, Brealey N, Brooks J, Criner G, Day N . Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018; 378(18):1671-1680. DOI: 10.1056/NEJMoa1713901. View

Rothnie K, Mullerova H, Smeeth L, Quint J . Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018; 198(4):464-471. PMC: 6118021. DOI: 10.1164/rccm.201710-2029OC. View

Rabe K, Martinez F, Ferguson G, Wang C, Singh D, Wedzicha J . Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020; 383(1):35-48. DOI: 10.1056/NEJMoa1916046. View

Garcia-Aymerich J, Serra Pons I, Mannino D, Maas A, Miller D, Davis K . Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax. 2011; 66(7):585-90. DOI: 10.1136/thx.2010.152876. View

Swart K, Baak B, Lemmens L, Penning-van Beest F, Bengtsson C, Lobier M . Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands. Respir Res. 2023; 24(1):293. PMC: 10662240. DOI: 10.1186/s12931-023-02601-4. View

Hurst J, Han M, Singh B, Sharma S, Kaur G, De Nigris E . Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022; 23(1):213. PMC: 9396841. DOI: 10.1186/s12931-022-02123-5. View

Moya-Alvarez V, Quevedo-Marin J, Ji Z, Navarro-Jimenez C, Jimenez-Garcia R, Lopez-de-Andres A . Variation in Assignment of the COPD Patients into a GOLD Group According to Symptoms Severity. Int J Chron Obstruct Pulmon Dis. 2020; 15:1987-1995. PMC: 7430767. DOI: 10.2147/COPD.S253445. View

Alter P, Lucke T, Watz H, Andreas S, Kahnert K, Trudzinski F . Cardiovascular predictors of mortality and exacerbations in patients with COPD. Sci Rep. 2022; 12(1):21882. PMC: 9763357. DOI: 10.1038/s41598-022-25938-0. View

10.

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

11.

Sadatsafavi M, Xie H, Etminan M, Johnson K, FitzGerald J . The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology. PLoS One. 2018; 13(1):e0191243. PMC: 5774719. DOI: 10.1371/journal.pone.0191243. View

12.

Polman R, Hurst J, Uysal O, Mandal S, Linz D, Simons S . Cardiovascular disease and risk in COPD: a state of the art review. Expert Rev Cardiovasc Ther. 2024; 22(4-5):177-191. DOI: 10.1080/14779072.2024.2333786. View

13.

Bhatta L, Leivseth L, Mai X, Henriksen A, Carslake D, Chen Y . GOLD Classifications, COPD Hospitalization, and All-Cause Mortality in Chronic Obstructive Pulmonary Disease: The HUNT Study. Int J Chron Obstruct Pulmon Dis. 2020; 15:225-233. PMC: 6999582. DOI: 10.2147/COPD.S228958. View

14.

Whittaker H, Rubino A, Mullerova H, Morris T, Varghese P, Xu Y . Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis. 2022; 17:427-437. PMC: 8901192. DOI: 10.2147/COPD.S346591. View

15.

Lokke A, Hilberg O, Lange P, Ibsen R, Stratelis G, de Fine Licht S . Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients. Int J Chron Obstruct Pulmon Dis. 2022; 17:569-578. PMC: 8937604. DOI: 10.2147/COPD.S344669. View

16.

Axson E, Bottle A, Cowie M, Quint J . Relationship between heart failure and the risk of acute exacerbation of COPD. Thorax. 2021; . PMC: 8311079. DOI: 10.1136/thoraxjnl-2020-216390. View

17.

Waeijen-Smit K, Jacobsen P, Houben-Wilke S, Simons S, Franssen F, Spruit M . All-cause admissions following a first ever exacerbation-related hospitalisation in COPD. ERJ Open Res. 2023; 9(1). PMC: 9808537. DOI: 10.1183/23120541.00217-2022. View

18.

Konecny T, Park J, Somers K, Konecny D, Orban M, Soucek F . Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol. 2014; 114(2):272-7. DOI: 10.1016/j.amjcard.2014.04.030. View

19.

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

20.

Vanfleteren L, Spruit M, Groenen M, Gaffron S, van Empel V, Bruijnzeel P . Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187(7):728-35. DOI: 10.1164/rccm.201209-1665OC. View